Sanofi snaps up acne vaccine developer Origimm BioSanofi has added to its vaccine pipeline with an agreement to acquire Austria’s Origimm Biotechnology and its vaccine-based Share XSanofi snaps up acne vaccine developer Origimm Biohttps://pharmaphorum.com/news/sanofi-snaps-up-acne-vaccine-developer-origimm-bio/
FDA hands Cassiopea its first approval, for acne drug WinleviItalian biotech Cassiopea has won US approval for Winlevi, a topical therapy it says is the first new Share XFDA hands Cassiopea its first approval, for acne drug Winlevihttps://pharmaphorum.com/news/fda-hands-cassiopea-its-first-approval-for-acne-drug-winlevi/
Foamix to file acne treatment after successful late-stage trialsIsrael’s Foamix has said it is planning a US filing of its minocycline-based topical acne treatment after positive late Share XFoamix to file acne treatment after successful late-stage trialshttps://pharmaphorum.com/news/foamix-to-file-acne-treatment-after-successful-late-stage-trials/
Sienna loses a quarter of its value over pivotal trial failureSienna Biopharmaceuticals said on Monday (30th July) that two pivotal trials of its main experimental acne treatment did Share XSienna loses a quarter of its value over pivotal trial failurehttps://pharmaphorum.com/news/sienna-loses-a-quarter-of-its-value-over-phase-3-trial-failure/
